Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL A GURBEL

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1003888520
CMS profile
181828
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,438.62

56 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,438.62 56

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL A GURBEL

NPI 1003888520 · CMS profile ID 181828

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003888520?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL A GURBEL, NPI 1003888520, CMS profile ID 181828. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003888520?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). PAUL A GURBEL, NPI 1003888520, CMS profile ID 181828. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003888520?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
PAUL A GURBEL, NPI 1003888520, CMS profile ID 181828, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1003888520?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

56 matching records · $1,438.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 56 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–56 of 56.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer HealthCare Pharmaceuticals Inc. $24.9401/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713633023 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $16.4101/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723077357 CMS
Actelion Pharmaceuticals US, Inc. $17.1301/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719345725 CMS
Novartis Pharmaceuticals Corporation $9.2201/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725772495 CMS
Amarin Pharma Inc. $13.9401/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739983407 CMS
Regeneron Healthcare Solutions, Inc. $13.0401/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724425425 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $9,689.50 68
PY2020 $1,438.62 56
PY2021 $1,993.41 72
PY2022 $11,376.44 59
PY2023 $1,400.43 70
PY2024 $1,484.23 62
PY2025 $2,038.34 73

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $173.25 2
PY2025 Principal investigator $634,705.67 23
PY2024 Recipient $18,995.79 4
PY2024 Principal investigator $412,309.53 16
PY2023 Principal investigator $126,609.98 13
PY2022 Principal investigator $482,256.98 22
PY2021 Principal investigator $372,365.48 34
PY2020 Recipient $10,000.00 1
PY2020 Principal investigator $191,745.66 6
PY2019 Principal investigator $361,674.13 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Haemonetics Corporation $14,400.00 12/31/2025 Covered Recipient Teaching Hospital
SINAI HOSPITAL OF BALTIMORE INC.
TARGET-ACS: THROMBOELASTOGRAPHY GUIDED APPROACH TO REDUCE THROMBOTIC AND BLEEDING EVENTS IN ACS PATIENTS No dispute reported 06/30/2026 1228049293
Principal investigator 1 Haemonetics Corporation $14,400.00 12/31/2025 Covered Recipient Teaching Hospital
SINAI HOSPITAL OF BALTIMORE INC.
TARGET-ACS: THROMBOELASTOGRAPHY GUIDED APPROACH TO REDUCE THROMBOTIC AND BLEEDING EVENTS IN ACS PATIENTS No dispute reported 06/30/2026 1228049300
Principal investigator 1 Novartis Pharmaceuticals Corporation $44.77 12/31/2025 Non-covered Recipient Entity
SINAI CENTER THROMBOIS RES DRUG DEV
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190310869
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,924.50 11/24/2025 Covered Recipient Teaching Hospital
Sinai Hospital Of Baltimore Inc.
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190296918
Principal investigator 1 Novartis Pharmaceuticals Corporation $834.67 11/04/2025 Non-covered Recipient Entity
SINAI CENTER THROMBOIS RES DRUG DEV
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190310873
Principal investigator 1 Haemonetics Corporation $12,667.20 10/20/2025 Covered Recipient Teaching Hospital
SINAI HOSPITAL OF BALTIMORE INC.
TARGET-ACS: THROMBOELASTOGRAPHY GUIDED APPROACH TO REDUCE THROMBOTIC AND BLEEDING EVENTS IN ACS PATIENTS No dispute reported 06/30/2026 1228049285
Principal investigator 1 Novartis Pharmaceuticals Corporation $527.88 08/25/2025 Non-covered Recipient Entity
SINAI CENTER THROMBOIS RES DRUG DEV
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190310875
Principal investigator 1 Eli Lilly and Company $62,199.00 08/18/2025 Covered Recipient Teaching Hospital
SINAI HOSPITAL OF BALTIMORE INC.
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 No dispute reported 06/30/2026 1187875073
Principal investigator 1 Eli Lilly and Company $167.35 06/09/2025 Covered Recipient Teaching Hospital
SINAI HOSPITAL OF BALTIMORE INC.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187873877
Principal investigator 1 Accriva Diagnostics Inc. $37,686.08 05/28/2025 Covered Recipient Teaching Hospital
Sinai Hospital of Baltimore, Inc.
Clinical Eval Protocol L0000026570 No dispute reported 06/30/2026 1223186290
Principal investigator 1 Eli Lilly and Company $8,757.73 04/27/2025 Covered Recipient Teaching Hospital
SINAI HOSPITAL OF BALTIMORE INC.
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 No dispute reported 06/30/2026 1187871371
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,768.70 03/26/2025 Non-covered Recipient Entity
SINAI CENTER THROMBOIS RES DRUG DEV
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190310871
Principal investigator 1 Eli Lilly and Company $171.73 03/18/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187893350
Principal investigator 1 Eli Lilly and Company $4,699.08 03/13/2025 Covered Recipient Teaching Hospital
SINAI HOSPITAL OF BALTIMORE INC.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187873875
Recipient Eli Lilly and Company $93.75 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187871215
Recipient Eli Lilly and Company $79.50 02/20/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187871101
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,530.72 01/28/2025 Non-covered Recipient Entity
SINAI HOSPITAL OF BALTIMORE
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190300071
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,142.60 01/17/2025 Non-covered Recipient Entity
SINAI HOSPITAL OF BALTIMORE
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190300067
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,573.48 01/15/2025 Non-covered Recipient Entity
SINAI CT FOR THROM RES AND DRUG DEV
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190310877
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,054.88 01/14/2025 Non-covered Recipient Entity
THE SINAI CENTER FOR THROMBOSIS RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190311921
Principal investigator 1 Haemonetics Corporation $8,975.60 01/09/2025 Covered Recipient Teaching Hospital
SINAI HOSPITAL OF BALTIMORE INC.
TARGET-ACS: THROMBOELASTOGRAPHY GUIDED APPROACH TO REDUCE THROMBOTIC AND BLEEDING EVENTS IN ACS PATIENTS No dispute reported 06/30/2026 1228049268
Principal investigator 1 Haemonetics Corporation $14,476.80 01/09/2025 Covered Recipient Teaching Hospital
SINAI HOSPITAL OF BALTIMORE INC.
TARGET-ACS: THROMBOELASTOGRAPHY GUIDED APPROACH TO REDUCE THROMBOTIC AND BLEEDING EVENTS IN ACS PATIENTS No dispute reported 06/30/2026 1228049277
Principal investigator 1 Eli Lilly and Company $118,906.03 01/07/2025 Covered Recipient Teaching Hospital
SINAI HOSPITAL OF BALTIMORE INC.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187871369
Principal investigator 1 Eli Lilly and Company $160,579.67 01/07/2025 Covered Recipient Teaching Hospital
SINAI HOSPITAL OF BALTIMORE INC.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187875071
Principal investigator 1 Novartis Pharmaceuticals Corporation $101,217.20 01/07/2025 Non-covered Recipient Entity
SINAI HOSPITAL OF BALTIMORE
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190300073